Section 5 of 6
Economic information and modeling report
1 evidence topic · 2 sources
Modeling overview
Summary: economic modeling and pricing status
No published cost-effectiveness analysis, budget impact model, or health technology assessment of bevacizumab-vikg has been identified. Outlook Therapeutics established a wholesale acquisition cost of $485 per vial for the United States on September 16, 2026, ahead of a planned U.S. commercial launch before the end of calendar 2026, and has stated that LYTENAVA has the potential to exceed $500 million in annual U.S. sales by 2030.
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.